Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality
© 2021. The Author(s), under exclusive licence to Springer Nature B.V. part of Springer Nature..
BACKGROUND: Coronavirus disease 2019 (COVID-19) is a respiratory disease associated with endotheliitis and microthrombosis.
OBJECTIVES: To correlate endothelial dysfunction to in-hospital mortality in a bi-centric cohort of COVID-19 adult patients.
METHODS: Consecutive ambulatory and hospitalized patients with laboratory-confirmed COVID-19 were enrolled. A panel of endothelial biomarkers and von Willebrand factor (VWF) multimers were measured in each patient ≤ 48 h following admission.
RESULTS: Study enrolled 208 COVID-19 patients of whom 23 were mild outpatients and 189 patients hospitalized after admission. Most of endothelial biomarkers tested were found increased in the 89 critical patients transferred to intensive care unit. However, only von Willebrand factor antigen (VWF:Ag) scaled according to clinical severity, with levels significantly higher in critical patients (median 507%, IQR 428-596) compared to non-critical patients (288%, 230-350, p < 0.0001) or COVID-19 outpatients (144%, 133-198, p = 0.007). Moreover, VWF high molecular weight multimers (HMWM) were significantly higher in critical patients (median ratio 1.18, IQR 0.86-1.09) compared to non-critical patients (0.96, 1.04-1.39, p < 0.001). Among all endothelial biomarkers measured, ROC curve analysis identified a VWF:Ag cut-off of 423% as the best predictor for in-hospital mortality. The accuracy of VWF:Ag was further confirmed in a Kaplan-Meier estimator analysis and a Cox proportional Hazard model adjusted on age, BMI, C-reactive protein and D-dimer levels.
CONCLUSION: VWF:Ag is a relevant predictive factor for in-hospital mortality in COVID-19 patients. More than a biomarker, we hypothesize that VWF, including excess of HMWM forms, drives microthrombosis in COVID-19.
| Errataetall: |
CommentIn: Angiogenesis. 2021 Aug;24(3):413-415. - PMID 34101095 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Angiogenesis - 24(2021), 3 vom: 15. Aug., Seite 505-517 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Philippe, Aurélien [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 29.07.2021 Date Revised 10.09.2022 published: Print-Electronic CommentIn: Angiogenesis. 2021 Aug;24(3):413-415. - PMID 34101095 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10456-020-09762-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320124983 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320124983 | ||
| 003 | DE-627 | ||
| 005 | 20231225172919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10456-020-09762-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320124983 | ||
| 035 | |a (NLM)33449299 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Philippe, Aurélien |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.07.2021 | ||
| 500 | |a Date Revised 10.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Angiogenesis. 2021 Aug;24(3):413-415. - PMID 34101095 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Springer Nature B.V. part of Springer Nature. | ||
| 520 | |a BACKGROUND: Coronavirus disease 2019 (COVID-19) is a respiratory disease associated with endotheliitis and microthrombosis | ||
| 520 | |a OBJECTIVES: To correlate endothelial dysfunction to in-hospital mortality in a bi-centric cohort of COVID-19 adult patients | ||
| 520 | |a METHODS: Consecutive ambulatory and hospitalized patients with laboratory-confirmed COVID-19 were enrolled. A panel of endothelial biomarkers and von Willebrand factor (VWF) multimers were measured in each patient ≤ 48 h following admission | ||
| 520 | |a RESULTS: Study enrolled 208 COVID-19 patients of whom 23 were mild outpatients and 189 patients hospitalized after admission. Most of endothelial biomarkers tested were found increased in the 89 critical patients transferred to intensive care unit. However, only von Willebrand factor antigen (VWF:Ag) scaled according to clinical severity, with levels significantly higher in critical patients (median 507%, IQR 428-596) compared to non-critical patients (288%, 230-350, p < 0.0001) or COVID-19 outpatients (144%, 133-198, p = 0.007). Moreover, VWF high molecular weight multimers (HMWM) were significantly higher in critical patients (median ratio 1.18, IQR 0.86-1.09) compared to non-critical patients (0.96, 1.04-1.39, p < 0.001). Among all endothelial biomarkers measured, ROC curve analysis identified a VWF:Ag cut-off of 423% as the best predictor for in-hospital mortality. The accuracy of VWF:Ag was further confirmed in a Kaplan-Meier estimator analysis and a Cox proportional Hazard model adjusted on age, BMI, C-reactive protein and D-dimer levels | ||
| 520 | |a CONCLUSION: VWF:Ag is a relevant predictive factor for in-hospital mortality in COVID-19 patients. More than a biomarker, we hypothesize that VWF, including excess of HMWM forms, drives microthrombosis in COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Endothelial activation | |
| 650 | 4 | |a Microthrombosis | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Multimers | |
| 650 | 4 | |a Von Willebrand factor | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a von Willebrand Factor |2 NLM | |
| 700 | 1 | |a Chocron, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Gendron, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Bory, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Beauvais, Agathe |e verfasserin |4 aut | |
| 700 | 1 | |a Peron, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Khider, Lina |e verfasserin |4 aut | |
| 700 | 1 | |a Guerin, Coralie L |e verfasserin |4 aut | |
| 700 | 1 | |a Goudot, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Levasseur, Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Peronino, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Duchemin, Jerome |e verfasserin |4 aut | |
| 700 | 1 | |a Brichet, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Sourdeau, Elise |e verfasserin |4 aut | |
| 700 | 1 | |a Desvard, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Bertil, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Pene, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Cheurfa, Cherifa |e verfasserin |4 aut | |
| 700 | 1 | |a Szwebel, Tali-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Planquette, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Rivet, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Jourdi, Georges |e verfasserin |4 aut | |
| 700 | 1 | |a Hauw-Berlemont, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Hermann, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Gaussem, Pascale |e verfasserin |4 aut | |
| 700 | 1 | |a Mirault, Tristan |e verfasserin |4 aut | |
| 700 | 1 | |a Terrier, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Diehl, Jean-Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Fontenay, Michaela |e verfasserin |4 aut | |
| 700 | 1 | |a Smadja, David M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Angiogenesis |d 1997 |g 24(2021), 3 vom: 15. Aug., Seite 505-517 |w (DE-627)NLM097524506 |x 1573-7209 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2021 |g number:3 |g day:15 |g month:08 |g pages:505-517 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10456-020-09762-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2021 |e 3 |b 15 |c 08 |h 505-517 | ||